We are excited to welcome Aukera Therapeutics as our newest portfolio company! Basel, Switzerland., 15 February 2022 — Aukera Therapeutics is a spin-off from the Biozentrum…
We are excited to welcome Stromal Therapeutics as our newest portfolio company! Basel, Switzerland., 28 January 2022 — Stromal Therapeutics is emerging from one of…
FDA greenlights Alentis Phase 1 protocol study design Alentis to begin transition from pre-clinical to clinical Basel, Switzerland., 04 January 2022 — Alentis Therapeutics, AG…
Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences to engineer highly potent and specific therapies based on…
Looking back, what a journey! We remember well when we first started working with Thomas Baumert in late 2017. Built on many years of transformational…
Synendos is developing first-in-class inhibitors. These inhibitors modulate a newly identified drug target in the body’s endocannabinoid system which is a key neuromodulator system in…
Polyneuron Pharmaceuticals, a BaseLaunch portfolio company, has concluded the extension of its Series A financing round. With further investment of 14 million francs, the startup has…